Selective Dose Escalation for Esophageal Cancer

• Status: Unknown status
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective study was designed to assess the outcomes (survival and failure patterns) of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy) with concurrent continuous infusion 5-fluorouracil (5-FU) and weekly carboplatin/paclitaxel. Patients with less than complete response (CR) or partial response (PR) received dose escalation of radiation to 59.4 Gy with the same chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Oregon Clinic
• Collaborators: Bristol-Myers Squibb; MedImmune LLC
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• T1-4, N0-1, M0-1a esophageal carcinoma

Exclusion Criteria:

• distant metastases